An array of experts came together in the panel discussion “HPV in Different Subsites—Clinical Importance and Effect on Therapy” to shed light on a variety of topics concerning human papillomavirus (HPV) status, including risk factors, the effectiveness of vaccinations, the use of biomarkers to predict response to cancer treatment, and guidance on treatment of adults.
Explore this issue:July 2014
Panel moderator Dinesh K. Chhetri, MD, head of the Swallowing Disorders Center at the University of California at Los Angeles, said the discussion provided an up-to-date overview of a topic that’s growing in importance. “I think we should be making physicians aware of this rising HPV epidemic … how it’s changing the landscape of the diseases affected, and how we should change our management as our understanding of the HPV-related diseases increases,” he said.
The prevalence of HPV infections among the healthy U.S. population is only 1%, according to National Health and Nutrition Examination Survey data. But oropharyngeal cancer among men is on the rise, due largely to a rise in HPV-positive cancers, said Carole Fakhry, MD, MPH, assistant professor of otolaryngology-head and neck surgery at Johns Hopkins University in Baltimore.| | | Next → | Single Page